Recent Updates
Recently added Catalysts
EUDA Positive Sentiment Score: 80/100

EUDA Accelerates Longevity Strategy with Launch of Comprehensive Stem Cell Therapy Platform and First Clinic in Shenzhen SINGAPORE

Key Takeaway: EUDA Health Holdings Limited has announced the launch of a comprehensive stem cell therapy platform and the establishment of its first clinic in Shenzhen, China. This initiative aims to accelerate its longevity and regenerative medicine strategy, supported by strategic partnerships and advanced technology. The upgraded facility will enhance production capabilities for stem cell treatments, and the new clinic will introduce integrated longevity healthcare services. This move positions EUDA to leverage the growing market for longevity-focused healthcare in Asia.

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of a comprehensive stem cell therapy platform.
  • Establishment of the first clinic in Shenzhen, enhancing access to longevity healthcare.
  • Partnerships with leading organizations to innovate in the longevity sector.
  • Upgrading the production facility to support advanced stem cell and T-cell therapies.

Full Press Release Details

Accelerates Longevity Strategy with Launch of Comprehensive Stem Cell Therapy Platform and First Clinic in Shenzhen
Dec. 23, 2025 (GLOBE NEWSWIRE) - EUDA Health Holdings Limited (NASDAQ: EUDA) "EUDA" or "the Company", a
Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced a significant acceleration
of its longevity and regenerative medicine strategy with the launch of a comprehensive stem cell therapy platform and establishment of
its first clinic in Shenzhen, China.
strategic advancement builds on the Company's earlier acquisition of distribution rights for T-cell immunotherapies developed by
Shenzhen Inno Immune Co. Ltd. ("Shenzhen Inno"), a developer of autologous cellular therapeutic and customized medicines
for a wide range of diseases in China, and its announced intention to acquire GO POSB Organoids Pte Ltd. ("GO POSB"), a biotechnology
company formed in Singapore.
Production and Innovation Center
is upgrading Shenzhen Inno's cGMP facility in Shenzhen to create a state-of-the-art production and innovation center for stem cell
treatments. This advancement incorporates GO POSB's proprietary induced pluripotent stem cell ("iPSC") technological
platform with advanced stem cell technologies sourced from two Japanese partners, including Japan Early Light Medical Corporation. The
enhanced cGMP facility will be essential for supporting iPSC expansion, stem cell preparation, immune cell therapies, and the development
of new treatments focused on immune health, skin health, and healthy aging. The Company and its partners will also explore cell-based
solutions using iPSC technology, which converts human blood cells into stem cells capable of becoming nearly any cell type.
of Shenzhen Longevity Clinic
parallel with the upgrade of Shenzhen Inno's cGMP facility, EUDA, in partnership with KB International Ltd., established a new
longevity clinic in Shenzhen. This clinic is strategically positioned to be the first in the region to comprehensively introduce Japanese
longevity healthcare technologies. It will offer a differentiated portfolio of services, including:
Advanced stem cell and T-cell immunotherapies produced at the upgraded GMP facility in Shenzhen;
Personalized AI-guided life cycle management; and
Integrated Eastern, Western, and functional medicine.
clinic will focus on enhancing longevity by slowing biological aging, strengthening immunity, and providing long-term health planning,
supported by partnerships with leading longevity institutions and hospitals in Japan, the United States, and Singapore.
Alfred Lim, CEO of EUDA, commented:
is a defining moment in EUDA's evolution. By combining an iPSC platform, expanding stem cell and t-cell therapies, the new upgraded
GMP facility's production capacity, and a fully integrated longevity clinic, we are building a comprehensive, end-to-end regenerative
ecosystem. Our robust partnerships with Shenzhen Inno, GO POSB, and the introduction of leading Japanese clinical expertise, positions
EUDA to capitalize on the fast-growing longevity sector and operate at the frontier of healthcare."
EUDA Health Holdings Limited
Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore,
Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the
fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which
is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and
science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment
to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.
document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words,
such as the words "estimates," "projected," "expects," "envisions," "anticipates,"
"forecasts," "plans," "intends," "believes," "seeks," "may,"
"will," "should," "future," "propose" and variations of these words or similar expressions
(or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions
or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are
outside EUDA's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking
statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document.
The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
Christensen Advisory
Phone: +1-480-614-3004

Frequently Asked Questions

What is EUDA Health's new initiative?

EUDA Health launched a stem cell therapy platform and opened its first clinic in Shenzhen.

Where is EUDA Health's first clinic located?

The first clinic is strategically established in Shenzhen, China.

What therapies will the Shenzhen clinic offer?

The clinic will provide advanced stem cell, T-cell immunotherapies, and personalized care.

What technology is used in the stem cell treatments?

The company employs an induced pluripotent stem cell platform for their therapies.

How does EUDA aim to improve healthcare?

EUDA focuses on preventive care and enhancing longevity through innovative health solutions.

Last updated: Dec 23, 2025